news – Page 21 – Medxy AI

Efficacy of Bictegravir-Based Regimen vs. Ritonavir-Boosted Protease Inhibitors in HIV Patients on Second-Line Therapy in Haiti: Insights from a Randomized Non-Inferiority Trial

By MedXY 09/21/2025

A randomized trial in Haiti demonstrates that switching to bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to ritonavir-boosted protease inhibitors in maintaining viral suppression among second-line HIV therapy patients.

Family Medicine & Nutrition news Specialties

Four Fruits You Shouldn’t Skimp On This Summer: Nature’s Skin-Boosting Superfoods

By MedXY 09/21/2025

Discover four summer fruits rich in vitamin C and antioxidants that boost skin health, hydration, immunity, and mood during harsh summer months.

Family Medicine & Nutrition Medical News news Specialties

The Double-Edged Sword of Curcumin: How Excessive Turmeric Supplements Can Harm Your Liver

By MedXY 09/21/2025

While turmeric's liver-regenerating benefits are celebrated, excessive intake of its active compound, curcumin, may cause serious liver damage. Understanding safe dosages and risks is critical for health.

Family Medicine & Nutrition Internal Medicine news Specialties

The Hidden Purines in Plant-Based Diets: What High Uric Acid Patients Need to Know

By MedXY 09/21/2025

High uric acid is linked to several diseases, and many avoid meat fearing purines. However, some vegetarian foods are high in purines too. Understanding these can help better manage uric acid levels and prevent complications like gout.

$Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial$

Clinical Updates news Oncology Specialties

Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial

By MedXY 09/21/2025

The PECATI phase 2 trial demonstrates that lenvatinib combined with pembrolizumab offers encouraging antitumour activity and a manageable safety profile in platinum-refractory metastatic B3 thymoma and thymic carcinoma, a population with limited treatment options.

Clinical Updates news Oncology Radiology Specialties

De-escalated Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Cancer: Balancing Efficacy with Reduced Toxicity

By MedXY 09/21/2025

This phase 3 trial shows that de-escalated adjuvant radiotherapy reduces chronic grade 3+ toxicities compared to standard chemoradiotherapy in HPV-associated oropharyngeal cancer, potentially improving patient quality of life without compromising treatment.

Cardiology news Specialties

Immediate Versus Staged Complete Revascularisation in STEMI with Multivessel Disease: Insights from the OPTION-STEMI Trial

By MedXY 09/21/2025

The OPTION-STEMI trial evaluated the safety and efficacy of immediate versus staged complete revascularisation during index admission in STEMI patients with multivessel disease, finding no non-inferiority of immediate approach at 1 year.

Cardiology news Specialties

Evolocumab and Saphenous Vein Graft Patency Post-CABG: Insights from the NEWTON-CABG Trial

By MedXY 09/21/2025

The NEWTON-CABG CardioLink-5 trial found that intensive LDL-C lowering with evolocumab did not improve saphenous vein graft patency 24 months after coronary artery bypass surgery despite significant LDL-C reductions.

news Pediatrics Specialties

Enhanced Respiratory Support in Very Preterm Infants: Nasal Mask CPAP Outperforms Face Mask at Birth

By MedXY 09/21/2025

An open-label RCT demonstrates that nasal mask CPAP at birth increases CPAP success rates and reduces the need for positive pressure ventilation compared to face mask CPAP in very preterm infants, with comparable safety profiles.

Neurology news Specialties

Candesartan 16 mg Shows Promise for Episodic Migraine Prevention: Results from a Robust Phase 2 Randomised Trial

By MedXY 09/21/2025

A multi-center, triple-blind phase 2 trial demonstrates that daily candesartan 16 mg significantly reduces migraine days in episodic migraine patients, with tolerable safety profiles, supporting its role as an effective preventive option.

Clinical Updates Hematology-Oncology news Specialties

Enhanced Progression-Free Survival with Ibrutinib Plus Rituximab in CXCR4-Mutated Waldenström Macroglobulinemia: Insights from a Pooled Analysis

By MedXY 09/21/2025

A pooled analysis of prospective studies shows ibrutinib plus rituximab improves progression-free survival in Waldenström macroglobulinemia patients with CXCR4 mutations compared to ibrutinib alone, supporting routine CXCR4 testing and combination treatment strategies.

$Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety$

Hematology-Oncology news Specialties

Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety

By MedXY 09/21/2025

Nanobody-based dual-targeting BCMA CAR T-cell therapy demonstrates high response rates and manageable safety in relapsed/refractory plasma cell myeloma, including high-risk subgroups.

Infectious Diseases news Specialties

Kissing Bugs and Chagas Disease: Understanding the Hidden Threat in the United States

By MedXY 09/21/2025

Approximately 280,000 Americans are infected with Chagas disease, transmitted by kissing bugs. This article explores the ecology, health risks, detection, and prevention of this often-overlooked disease.

Clinical Updates news Oncology Radiology

Expanding the Role of Stereotactic Radiosurgery in Small Cell Lung Cancer with Brain Metastases: Insights from a Prospective Multicenter Phase II Trial

By MedXY 09/21/2025

A prospective phase II trial shows stereotactic radiosurgery offers a low neurologic death rate in SCLC patients with 1-10 brain metastases, challenging the traditional favoring of whole-brain radiation therapy.

Hematology-Oncology news Specialties

PET-Guided BrECADD Therapy: A Breakthrough for Older Patients with Advanced-Stage Classic Hodgkin Lymphoma

By MedXY 09/21/2025

This phase II HD21 trial cohort demonstrates that PET-guided BrECADD chemotherapy is feasible, effective, and well-tolerated in older patients with advanced-stage classic Hodgkin lymphoma, achieving high complete remission and survival rates.

news Oncology Specialties

Dual Immune Checkpoint Blockade Fails to Improve Outcomes in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007 Phase II Study Results

By MedXY 09/21/2025

The NRG Oncology BN007 trial found that combining ipilimumab with nivolumab did not improve progression-free survival compared to temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma, leading to early closure of the study before phase III.

news Oncology Specialties

Obrixtamig (BI 764532): A Promising DLL3/CD3 T-Cell Engager in Heavily Pretreated DLL3-Positive Neuroendocrine Cancers

By MedXY 09/21/2025

Phase I trial of obrixtamig, a DLL3/CD3 T-cell engager, shows tolerability and encouraging efficacy in heavily pretreated patients with DLL3-positive SCLC and neuroendocrine carcinomas, supporting further development.

Clinical Updates General Surgery news Oncology Specialties

Innovative Combination of Cryoablation and Intratumoral Immunotherapy Extends Survival in Advanced Metastatic Cancer

By MedXY 09/21/2025

A phase II trial demonstrates that multiplex intratumoral immunotherapy combining cryoablation with low-dose immune checkpoint inhibitors significantly prolongs median overall survival to 20.9 months in treatment-refractory metastatic solid tumors.

Gastroenterology news Specialties

The Withdrawal of OCALIVA: Impact and Implications for Primary Biliary Cholangitis Treatment

By MedXY 09/21/2025

Intercept Pharmaceuticals withdraws OCALIVA from the US market following FDA demands due to safety concerns and lack of proven efficacy in PBC, prompting suspension of related clinical trials and significant shifts in therapeutic landscape.

Clinical Updates Infectious Diseases news Specialties

PegIFN Alpha-2a Therapy Reduces Relapse Risk after NUC Discontinuation in HBeAg-Negative Chronic Hepatitis B: Insights from a Randomized Controlled Trial

By MedXY 09/21/2025

Switching from nucleo(s)tide analogues to pegylated interferon alpha-2a significantly lowers virological relapse and boosts HBsAg clearance in HBeAg-negative chronic hepatitis B patients after treatment cessation.